Clinical Trial Details
— Status: Not yet recruiting
Administrative data
| NCT number |
NCT04987827 |
| Other study ID # |
ICON |
| Secondary ID |
|
| Status |
Not yet recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
November 1, 2021 |
| Est. completion date |
June 30, 2023 |
Study information
| Verified date |
July 2021 |
| Source |
Ruijin Hospital |
| Contact |
Jieming Qu |
| Phone |
86-021-64370045 |
| Email |
jmqu0906[@]163.com |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Bronchiectasis is a chronic respiratory disease characterized by permanent bronchiectasis.The
incidence and prevalence of bronchiectasis have assumed continuously grows in global.
Different from overseas, bronchiectasis is common disease in China. This study will collect
data from the real-world bronchiectasis database and follow up for one year, describe the
bronchiectasis exacerbation rate and proportions for frequent exacerbation, clinical features
and prognosis of bronchiectasis exacerbation, the treatment pattern (when clinically stable)
during follow-up period; and describe characteristics of bronchiectasis at baseline. This
study will also explore potential baseline risk factors for bronchiectasis exacerbation
during follow-up period.
Description:
Bronchiectasis is a chronic respiratory disease characterized by permanent bronchiectasis,
its main clinical symptoms are cough, dyspnea, hemoptysis and recurrent respiratory tract
infections. The incidence and prevalence of bronchiectasis have assumed continuously grows in
global. Different from overseas, bronchiectasis is common disease in China. In 2013, the
prevalence rate of bronchiectasis in Chinese residents over 40 years old was 1,200/100,000.
As lack of large epidemiological data in China, the prevalence rate may still be
underestimated, which needs more attention and research.
Bronchiectasis has heavy disease burden, characterized by recurrent acute exacerbations, high
mortality, poor prognosis and heavy economic burden. The key points of bronchiectasis
treatment strategy include exacerbation prevention, number of exacerbations reduction,
prognosis improvement and then the quality of patients' life improvement. Therefore, it is
important to describe the clinical features and prognosis of bronchiectasis (especially the
incidence of acute exacerbations and the proportion of frequent exacerbations), and it would
be helpful to understand the characteristics of bronchiectasis and standardize related
diagnosis and treatment strategy.
This study will collect data from the real-world bronchiectasis database and follow up for
one year, describe the bronchiectasis exacerbation rate and proportions for frequent
exacerbation, clinical features and prognosis of bronchiectasis exacerbation, the treatment
pattern (when clinically stable) during follow-up period; and describe characteristics of
bronchiectasis at baseline. This study will also explore potential baseline risk factors for
bronchiectasis exacerbation during follow-up period.
